logo
Timothy J. Cavanagh: Illinois toxic tort law would prevent out-of-state companies from evading accountability

Timothy J. Cavanagh: Illinois toxic tort law would prevent out-of-state companies from evading accountability

Chicago Tribune21-07-2025
Every Illinoisan deserves to live and work in a safe environment free from hazardous, life-threatening conditions. Yet when our residents travel to other states, they may face repeated exposure to asbestos or other highly toxic substances and be vulnerable to serious illness if they were not provided proper protective clothing and breathing equipment.
Out-of-state companies too often escape accountability for exposing individuals to dangerous materials, leaving them to suffer devastating health consequences with little legal recourse short of the expensive, time-consuming and impractical option of pursuing lawsuits in those other states.
A bill, SB328, recently passed by the General Assembly and now under Gov. JB Pritzker's consideration, solves that dilemma by permitting a person filing a case in an Illinois court to include out-of-state companies as defendants.
By strengthening the ability of Illinois residents to seek justice against all responsible parties, this legislation would help promote healthier, safer working conditions by putting businesses, regardless of where they are headquartered, on notice that they are responsible for protecting Illinoisans from preventable harms.
To be clear, this legislation applies in relatively limited circumstances. SB328 does not expose Illinois-based businesses to litigation to which they are not already subject under current law. To involve companies not located in the state, but doing business here, a plaintiff must first file a case in Illinois against at least one defendant that would be subject to the specific jurisdiction of an Illinois court. Only then, contingent upon a judge's approval, could other relevant out-of-state businesses be added to the case.
Additionally, this legislation pertains only to toxic substances as defined by the Illinois Uniform Hazardous Substances Act. One such example familiar to most people would be asbestos, because of its sad and long history in our country of sickening hundreds of thousands of people and condemning them to prolonged and painful deaths.
If you've seen the suffering caused by the careless use of asbestos up close, you would understand why it is important to send a strong message that companies using toxic substances need to take sufficient care to protect people from being harmed by them. And, if they fail to do so, they deserve significant financial punishment to deter them and others from persisting in unsafe practices.
The fearmongering from Illinois business organizations about the bill borders on hysteria. Despite what they say, prescription drugs, baby formula, beverages and food products are not a part of the bill for the simple reason they aren't made with highly toxic ingredients.
Opponents also say New York rejected the same bill. Not true. New York's was far more expansive and, beyond businesses, included nonprofits and governmental entities.
Finally, those against the bill argue it would make Illinois an outlier. But, in reality, other states have laws that say anyone transacting business in them consents to the jurisdiction of their courts. Pennsylvania already has a far broader toxic tort law than what is proposed in Illinois, and I have yet to see any news coverage about the cessation of business in the Steel City, the City of Brotherly Love or all the many towns between the two.
Opposition from Illinois corporate associations to this legislation is puzzling, since it actually levels the playing field for Illinois companies by holding those from out of state to the same standard as applies to those that are based here.
The bill's merits are attested to by the diversity of its supporters, which include dozens of trade and service unions represented by the Illinois AFL-CIO; the multitude of local and national environmental organizations that work collaboratively through the Illinois Environmental Council; and Citizen Action, the state's largest public interest organization that advocates for policies to protect the health and well-being of all Illinoisans.
By reinforcing corporate accountability, this bill complements Illinois' ongoing efforts to strengthen environmental protections and public health safeguards. It sends a clear message and commonsense message: Companies that profit from doing business here must accept the responsibility of protecting the people and environment they impact.
With the Donald Trump administration choosing to stop enforcing various environmental protections and, shockingly, reconsidering the ban on cancer-causing asbestos put in place by the previous administration, it is vital that states step into the breach. Pritzker's signature on SB328 will send a clear message that Illinois is leaving no stone unturned when it comes to protecting the public's health.
Timothy J. Cavanagh is founder of Cavanagh Sorich Law Group in Chicago and president of the Illinois Trial Lawyers Association.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion
AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

Yahoo

time8 hours ago

  • Yahoo

AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion

On Thursday, AbbVie Inc. (NYSE:ABBV) reported second-quarter 2025 sales of $15.42 billion on Thursday, beating the consensus of $14.98 billion. Sales increased 6.6% on a reported basis or 6.5% on an operational basis. The company reported adjusted earnings of $2.97, up 12.1% year over year and missing the consensus of $3.23. AbbVie raised its fiscal 2025 adjusted earnings from $11.67-$11.87 per share to $11.88-$12.08 compared to the analysts' estimate of $12.24.'While management indicated that they expect some moderation in net pricing in the second half, the volume growth we are seeing from these products gives us added confidence in the company's outlook for the second half of 2025 and the coming years,' Guggenheim Partners wrote in an investor note on Thursday. Guggenheim updated its model to reflect the quarterly performance, including higher Skyrizi and neuroscience estimates, a steeper Humira erosion curve, and slightly lower aesthetics estimates, resulting in new 2025E revenue/EPS of $60.69 billion/$12.04, up from $60.02 billion/$11.92, respectively. View more earnings on ABBV Analyst Vamil Divan says Skyrizi and Rinvoq are now tracking ahead of management's prior long-term targets. Guggenheim expects those targets will likely be increased further by the time the company releases its fiscal 2025 earnings in February next year. The analyst reiterates a Buy rating, increasing the price forecast from $216 to $227. 'We acknowledge that the Part D Redesign provision of the Inflation Reduction Act may affect drug prices in an unexpected way in the back half of the we generally do not expect a dramatic increase in pricing pressure on ABBV's portfolio relative to the first half of the year...,' the analyst wrote. Mirroring the positive sentiment, Morgan Stanley has maintained AbbVie as an Overweight and has raised the price forecast from $250 to $255. Price Action: ABBV stock is trading higher by 3.24% to $195.14 at last check Friday. Read Next:Photo via Shutterstock Latest Ratings for ABBV Date Firm Action From To Feb 2022 UBS Downgrades Buy Neutral Feb 2022 Mizuho Maintains Buy Feb 2022 Barclays Maintains Equal-Weight View More Analyst Ratings for ABBV View the Latest Analyst Ratings UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets. Get the latest stock analysis from Benzinga? This article AbbVie Soars On Skyrizi And Rinvoq Strength, Outpacing Humira Erosion originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Delta Air assures US lawmakers it will not personalize fares using AI
Delta Air assures US lawmakers it will not personalize fares using AI

CNBC

time8 hours ago

  • CNBC

Delta Air assures US lawmakers it will not personalize fares using AI

Delta Air Lines said on Friday it will not use artificial intelligence to set personalized ticket prices for passengers after facing sharp criticism from U.S. lawmakers and broad public concern. Last week, Democratic Senators Ruben Gallego, Mark Warner and Richard Blumenthal said they believed the Atlanta-based airline would use AI to set individual prices, which would "likely mean fare price increases up to each individual consumer's personal 'pain point.'" Delta said it has not used AI to set personalized prices but previously said it plans to deploy AI-based revenue management technology across 20% of its domestic network by the end of 2025 in partnership with Fetcherr, an AI pricing company. "There is no fare product Delta has ever used, is testing or plans to use that targets customers with individualized prices based on personal data," Delta told the senators in a letter on Friday, seen by Reuters. "Our ticket pricing never takes into account personal data." Senators praised Delta's commitment not to use AI for personal pricing but expressed many questions and want more details about what data Delta is collecting to set prices. "Delta is telling their investors one thing, and then turning around and telling the public another," Gallego said. "If Delta is in fact using aggregated instead of individualized data, that is welcome news." Delta declined comment on Gallego's statement. The senators cited a comment in December by Delta President Glen Hauenstein that the carrier's AI price-setting technology is capable of setting fares based on a prediction of "the amount people are willing to pay for the premium products related to the base fares." Last week, American Airlines CEO Robert Isom said using AI to set ticket prices could hurt consumer trust. "This is not about bait and switch. This is not about tricking," Isom said on an earnings call, adding "talk about using AI in that way, I don't think it's appropriate. And certainly from American, it's not something we will do." Democratic lawmakers Greg Casar and Rashida Tlaib last week introduced legislation to bar companies from using AI to set prices or wages based on Americans' personal data and would specifically ban airlines raising individual prices after seeing a search for a family obituary. They cited a Federal Trade Commission staff report in January that found "retailers frequently use people's personal information to set targeted, tailored prices for goods and services -- from a person's location and demographics, down to their mouse movements on a webpage." The FTC cited a hypothetical example of a consumer profiled as a new parent who could intentionally be shown higher-priced baby thermometers and collect behavioral details to forecast a customer's state of mind. Delta said airlines have used dynamic pricing for more than three decades, in which pricing fluctuates based on a variety of factors like overall customer demand, fuel prices and competition, but not a specific consumer's personal information. "Given the tens of millions of fares and hundreds of thousands of routes for sale at any given time, the use of new technology like AI promises to streamline the process by which we analyze existing data and the speed and scale at which we can respond to changing market dynamics," Delta's letter said.

Delta Air Lines assures U.S. lawmakers it will not personalize fares using AI
Delta Air Lines assures U.S. lawmakers it will not personalize fares using AI

NBC News

time10 hours ago

  • NBC News

Delta Air Lines assures U.S. lawmakers it will not personalize fares using AI

WASHINGTON - Delta Air Lines said on Friday it will not use artificial intelligence to set personalized ticket prices for passengers after facing sharp criticism from U.S. lawmakers and broad public concern. Last week, Democratic Senators Ruben Gallego, Mark Warner and Richard Blumenthal said they believed the Atlanta-based airline would use AI to set individual prices, which would 'likely mean fare price increases up to each individual consumer's personal 'pain point.'' Delta said it has not used AI to set personalized prices but previously said it plans to deploy AI-based revenue management technology across 20% of its domestic network by the end of 2025 in partnership with Fetcherr, an AI pricing company. 'There is no fare product Delta has ever used, is testing or plans to use that targets customers with individualized prices based on personal data,' Delta told the senators in a letter on Friday, seen by Reuters. 'Our ticket pricing never takes into account personal data.' Senators praised Delta's commitment not to use AI for personal pricing but expressed many questions and want more details about what data Delta is collecting to set prices. 'Delta is telling their investors one thing, and then turning around and telling the public another,' Gallego said. 'If Delta is in fact using aggregated instead of individualized data, that is welcome news.' Delta declined comment on Gallego's statement. The senators cited a comment in December by Delta President Glen Hauenstein that the carrier's AI price-setting technology is capable of setting fares based on a prediction of 'the amount people are willing to pay for the premium products related to the base fares.' Last week, American Airlines CEO Robert Isom said using AI to set ticket prices could hurt consumer trust. 'This is not about bait and switch. This is not about tricking,' Isom said on an earnings call, adding 'talk about using AI in that way, I don't think it's appropriate. And certainly from American, it's not something we will do.' Democratic lawmakers Greg Casar and Rashida Tlaib last week introduced legislation to bar companies from using AI to set prices or wages based on Americans' personal data and would specifically ban airlines raising individual prices after seeing a search for a family obituary. They cited a Federal Trade Commission staff report in January that found 'retailers frequently use people's personal information to set targeted, tailored prices for goods and services -- from a person's location and demographics, down to their mouse movements on a webpage.' The FTC cited a hypothetical example of a consumer profiled as a new parent who could intentionally be shown higher-priced baby thermometers and collect behavioral details to forecast a customer's state of mind. Delta said airlines have used dynamic pricing for more than three decades, in which pricing fluctuates based on a variety of factors like overall customer demand, fuel prices and competition, but not a specific consumer's personal information. 'Given the tens of millions of fares and hundreds of thousands of routes for sale at any given time, the use of new technology like AI promises to streamline the process by which we analyze existing data and the speed and scale at which we can respond to changing market dynamics,' Delta's letter said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store